Company news

Avalo Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Avalo to Participate in SVB Securities Therapeutics Forum

July 5, 2023

Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma

June 25, 2023

Avalo to Present at the Jefferies Healthcare Conference

May 31, 2023

Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D. to its Scientific Advisory Board

May 21, 2023

Avalo to Present at ATS 2023 Respiratory Innovation Summit

May 14, 2023

Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference

May 9, 2023

Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates

May 3, 2023

Avalo Reports 2022 Financial Results and Provides Business Updates

March 28, 2023

Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference

March 6, 2023

Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants

February 1, 2023

Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants

February 1, 2023

Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma

January 16, 2023

Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million

November 6, 2022

Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates

November 6, 2022

Avalo Advances BTLA Agonist Fusion Protein (AVTX-008) to IND-enabling Stage

September 5, 2022

Avalo to Present at the H.C. Wainwright Global Investment Conference

August 31, 2022

Avalo Therapeutics Announces Board Changes

August 10, 2022

Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates

August 3, 2022

Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)

August 1, 2022

Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics

July 31, 2022

Avalo Therapeutics Announces One-for-Twelve Reverse Stock Split

July 5, 2022

Avalo to Present at the 2022 Jefferies Healthcare Conference

June 1, 2022

Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma (NEA)

May 17, 2022

Avalo to Present at the H.C. Wainwright Global Life Sciences Conference

May 16, 2022

Avalo Therapeutics First Quarter 2022 Financial Results and Business Updates

May 4, 2022

Avalo to Present at Oppenheimer's 32nd Annual Healthcare Conference

March 7, 2022

Avalo Therapeutics Reports 2021 Financial Results and Provides Business Updates

March 1, 2022

Avalo Therapeutics Announces Leadership Transition

February 16, 2022

Avalo Therapeutics to Present at the 2022 BIO CEO and Investor Conference

February 6, 2022

Avalo Therapeutics Appoints Stephen Smolinski as Chief Commercial Officer

January 9, 2022

Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event

January 5, 2022

Avalo Therapeutics to Host Virtual Investor Day on January 6, 2022

December 15, 2021

Avalo Appoints Two New Independent Directors to Its Board

December 5, 2021

Avalo to Present at Two Upcoming Conferences

November 10, 2021

Avalo Reports Third Quarter 2021 Financial Results and Provides Business Updates

November 8, 2021

Avalo to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit

October 12, 2021

Avalo Therapeutics, Inc. Announces Closing of a $31.5 Million Public Offering of Common Stock, Including Proceeds from Exercise of Option to Purchase Additional Shares

September 16, 2021

Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

September 13, 2021

Avalo Therapeutics, Inc. Announces Pricing of $27.5 Million Public Offering of Common Stock

September 13, 2021

← Newer news releases

Calls

Decks

The 5 newest of 41 decks. Every deck is listed under its year.